Top Markets
#1 MowCat MowCat +49.07%
#2 Velvet Velvet +36.37%
#3 Derive Derive +21.24%
#4 Quack AI Quack AI +19.75%
#5 Audiera Audiera +19.69%
#6 MarsCoin MarsCoin +16.65%
#7 Bermuda Shorts Bermuda Shorts +16.51%
#8 aPriori aPriori +15.29%
#9 Biconomy Biconomy +13.82%
#10 Geodnet Geodnet +12.49%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Medigene AG Medigene AG

Medigene AG

MDG1
Rank in Stocks #35468
Medigene AG is a German biotechnology company primarily focused on innovating T... Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.
Share Price
$0.14942078
Last synced: 2025-05-15
Market Cap
$3.86M
Change (1 day)
0.10%
Change (1 year)
0.00%
Country
DE
Trade Medigene AG (MDG1)

Category

Healthcare
Revenue for Medigene AG (MDG1)
Revenue in Jun 2024 TTM: $7.99M
According to Medigene AG latest financial reports the company's current revenue (TTM) is $7.99M. In 2022 the company made a revenue of $33.52M an increase over the revenue in the year 2021 that was $11.90M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Medigene AG from 2004 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $7.99M 19.85%
2023 $6.67M -80.10%
2022 $33.52M 181.71%
2021 $11.90M 22.09%
2020 $9.75M -17.36%
2019 $11.79M 35.46%
2018 $8.71M -5.48%
2017 $9.21M 113.45%
2016 $4.32M 28.15%
2015 $3.37M -77.88%
2014 $15.22M 46.65%
2013 $10.38M 34.07%
2012 $7.74M 160.02%
2011 $2.98M 0.59%
2010 $2.96M -94.55%
2009 $54.28M 16.25%
2008 $46.70M 44.83%
2007 $32.24M -19.79%
2006 $40.20M 73.97%
2005 $23.11M 36.31%
2004 $16.95M 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 157,814.80%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 75,219.06%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 126,373.78%
BE